Available Trials

---

• Breast
• Cholangiocarcinoma
• Colorectal/GI/Gastrointestinal
• Endometrial
• Head/Neck
• Lung - Non-Small Cell Lung
• Lung - Small Cell Lung
• Lymphoma
• Solid Tumor
• STAR: Selected Trials Available for Accelerated Four Week Rollout

---

Breast

• USOR 24151 - Ph3 study of standard endocrine therapy with breast cancer

  Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 22159 - Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

  A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
  

  Available at Arlington Heights, Niles

---

Cholangiocarcinoma

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles, Chicago Resurrection

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles

---

Colorectal/GI/Gastrointestinal

• USOR 24093 - Ph3 study of T-DXd vs SOC gemcitabine for HER2-expressing Biliary Tract Cancer

  DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC00001)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

---

Endometrial

• USOR 22242 - Ph3 Selin P53 Endo Carcinoma

  A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
  

  Available at Arlington Heights

---

Head/Neck

• USOR 23234 - Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)

  A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC), D798EC00001
  

  Available at Arlington Heights, Niles

• USOR 24004 - STAR Ph3 study to evaluate to treat patients with HNSCC

  A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
  

  Available at Arlington Heights, Niles

---

Lung - Non-Small Cell Lung

• USOR 24018 - STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

  A phase 3 randomized, open-label, multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 22118 - Ph3 Soto/Doublet vs Pembro/Doublet NSCLC PD-L1 neg KRAS PG12C+ (CodeBreaK 202)

  A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (20190341)
  

  Available at Arlington Heights, Niles

• USOR 21318 - STAR: PH1/3 Biomarker unresectable stg3 NSCLC

  A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer
  

  Available at Arlington Heights, Niles

• USOR 23235 - Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

  A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)
  

  Available at Arlington Heights, Niles

• USOR 23074 - Ph3 SGN-B6A vs docetaxel NSCLC

  A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)
  

  Available at Arlington Heights, Niles

• USOR 22229 - Ph3 Dato-Dxd Pembro PD-L1 < 50% NSCLC (TL07)

  A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
  

  Available at Arlington Heights, Niles

• USOR 21541 - Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%

  A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
  

  Available at Arlington Heights, Niles

• USOR 22285 - MYLUNG Consortium Part 3: Observational Study

  Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)
  

  Available at Arlington Heights, Niles

• USOR 20270 - Ph2 MRTX849 Pembro NSCLC KRAS

  A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. (849-007) (Mirati Therapeutics)
  

  Available at Arlington Heights, Niles

---

Lung - Small Cell Lung

• USOR 24312 - Randomized study of BMS-986489 vs durvalumab in limited stage SCLC (TIGOS-LS)

  An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23243 - Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

  A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)
  

  Available at Arlington Heights, Niles

---

Lymphoma

• USOR 19062 - Ph 1b/3 Taze w/ R2 R/R Fol Lymph

  A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)
  

  Available at Arlington Heights, Niles

---

Solid Tumor

• USOR 23253 - STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

  Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23328 - STAR Ph2 study of BI 1810631 for the treatment of HER-2 mutated solid tumors

  Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours (1479-0009)
  

  Available at Arlington Heights, Niles

• USOR 22037 - STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

  A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
  

  Available at Arlington Heights, Niles

• USOR 19151 - STAR Ph1/2 MRTX849 Solids KRAS G12C

  A Phase 1/2, Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
  

  Available at Niles

---

STAR: Selected Trials Available for Accelerated Four Week Rollout

• USOR 24018 - STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

  A phase 3 randomized, open-label, multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23253 - STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

  Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles, Chicago Resurrection

• USOR 22037 - STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

  A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
  

  Available at Arlington Heights, Niles

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles

• USOR 24004 - STAR Ph3 study to evaluate to treat patients with HNSCC

  A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
  

  Available at Arlington Heights, Niles

• USOR 21318 - STAR: PH1/3 Biomarker unresectable stg3 NSCLC

  A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer
  

  Available at Arlington Heights, Niles